Evotec SE ADR (EVO) - Net Assets

Latest as of September 2025: $800.14 Million USD

Based on the latest financial reports, Evotec SE ADR (EVO) has net assets worth $800.14 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.77 Billion) and total liabilities ($972.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Evotec SE ADR (EVO) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$800.14 Million
% of Total Assets	45.14%
Annual Growth Rate	16.87%
5-Year Change	7.46%
10-Year Change	409.12%
Growth Volatility	37.68

Evotec SE ADR - Net Assets Trend (2003–2024)

This chart illustrates how Evotec SE ADR's net assets have evolved over time, based on quarterly financial data. Also explore EVO asset base for the complete picture of this company's asset base.

Annual Net Assets for Evotec SE ADR (2003–2024)

The table below shows the annual net assets of Evotec SE ADR from 2003 to 2024. For live valuation and market cap data, see EVO market cap overview.

Year	Net Assets	Change
2024-12-31	$952.52 Million	-14.95%
2023-12-31	$1.12 Billion	-5.67%
2022-12-31	$1.19 Billion	-13.83%
2021-12-31	$1.38 Billion	+55.42%
2020-12-31	$886.41 Million	+65.54%
2019-12-31	$535.47 Million	+26.03%
2018-12-31	$424.88 Million	+28.07%
2017-12-31	$331.75 Million	+55.07%
2016-12-31	$213.94 Million	+14.35%
2015-12-31	$187.09 Million	+18.13%
2014-12-31	$158.38 Million	-0.37%
2013-12-31	$158.97 Million	+4.21%
2012-12-31	$152.55 Million	+3.60%
2011-12-31	$147.25 Million	+11.01%
2010-12-31	$132.64 Million	+18.97%
2009-12-31	$111.49 Million	-25.61%
2008-12-31	$149.86 Million	-12.13%
2007-12-31	$170.55 Million	+24.33%
2006-12-31	$137.18 Million	-7.73%
2005-12-31	$148.67 Million	+140.85%
2004-12-31	$61.73 Million	+71.32%
2003-12-31	$36.03 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Evotec SE ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 67237000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	$177.55 Million	18.64%
Other Comprehensive Income	$-7.35 Million	-0.77%
Other Components	$1.45 Billion	152.72%
Total Equity	$952.52 Million	100.00%

Evotec SE ADR Competitors by Market Cap

The table below lists competitors of Evotec SE ADR ranked by their market capitalization.

Company	Market Cap
Energy Resources of Australia Ltd AU:ERA	$1.15 Billion
Isras Investment Company Ltd TA:ISRS	$1.15 Billion
Olema Pharmaceuticals Inc NASDAQ:OLMA	$1.15 Billion
China Union Holdings Ltd SHE:000036	$1.15 Billion
Arcos Dorados Holdings Inc NYSE:ARCO	$1.15 Billion
Fujian Septwolves Industry Co Ltd SHE:002029	$1.15 Billion
Teladoc Inc NYSE:TDOC	$1.15 Billion
Shanghai Zhezhong Construction Co Ltd SHE:002346	$1.15 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Evotec SE ADR's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 1,119,908,000 to 952,525,000, a change of -167,383,000 (-14.9%).
Net loss of 196,078,000 reduced equity.
Other comprehensive income increased equity by 23,296,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	$-196.08 Million	-20.59%
Other Comprehensive Income	$23.30 Million	+2.45%
Other Changes	$5.40 Million	+0.57%
Total Change	$-	-14.95%

Book Value vs Market Value Analysis

This analysis compares Evotec SE ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.20x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 0.06x to 1.20x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-12-31	$57.82	$3.23	x
2002-12-31	$15.64	$3.23	x
2003-12-31	$-34.72	$3.23	x
2004-12-31	$1.41	$3.23	x
2005-12-31	$2.76	$3.23	x
2006-12-31	$2.34	$3.23	x
2007-12-31	$1.19	$3.23	x
2008-12-31	$0.79	$3.23	x
2009-12-31	$0.52	$3.23	x
2010-12-31	$0.61	$3.23	x
2011-12-31	$0.63	$3.23	x
2012-12-31	$0.65	$3.23	x
2013-12-31	$0.66	$3.23	x
2014-12-31	$0.60	$3.23	x
2015-12-31	$0.67	$3.23	x
2016-12-31	$0.80	$3.23	x
2017-12-31	$1.14	$3.23	x
2018-12-31	$1.44	$3.23	x
2019-12-31	$1.79	$3.23	x
2020-12-31	$2.88	$3.23	x
2021-12-31	$4.14	$3.23	x
2022-12-31	$3.36	$3.23	x
2023-12-31	$6.33	$3.23	x
2024-12-31	$2.69	$3.23	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Evotec SE ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -20.59%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -24.60%
• Asset Turnover: 0.42x
• Equity Multiplier: 2.01x
Recent ROE (-20.59%) is below the historical average (-14.14%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	-35.26%	0.00%	0.00x	1.00x	$-16.39 Million
2002	-127.77%	0.00%	0.00x	1.00x	$-25.77 Million
2003	0.00%	-930.49%	0.09x	0.00x	$-27.01 Million
2004	-48.25%	-1521.56%	0.03x	1.16x	$-35.57 Million
2005	-22.59%	-52.38%	0.34x	1.25x	$-48.45 Million
2006	-23.67%	-48.21%	0.33x	1.50x	$-46.19 Million
2007	-6.54%	-33.92%	0.16x	1.22x	$-28.21 Million
2008	-52.24%	-197.63%	0.22x	1.22x	$-93.27 Million
2009	-41.03%	-106.59%	0.29x	1.32x	$-56.58 Million
2010	2.47%	5.90%	0.29x	1.45x	$-9.96 Million
2011	4.58%	8.42%	0.37x	1.48x	$-7.98 Million
2012	1.62%	2.84%	0.39x	1.48x	$-12.78 Million
2013	-16.00%	-29.59%	0.38x	1.43x	$-41.33 Million
2014	-4.41%	-7.80%	0.40x	1.42x	$-22.82 Million
2015	8.90%	12.94%	0.44x	1.56x	$-2.03 Million
2016	12.92%	16.73%	0.47x	1.65x	$6.23 Million
2017	7.33%	9.42%	0.39x	2.02x	$-8.82 Million
2018	19.85%	22.42%	0.49x	1.82x	$41.77 Million
2019	7.13%	8.55%	0.32x	2.58x	$-15.39 Million
2020	0.71%	1.25%	0.27x	2.07x	$-82.36 Million
2021	15.64%	34.87%	0.28x	1.62x	$77.74 Million
2022	-14.80%	-23.38%	0.33x	1.90x	$-294.37 Million
2023	-7.49%	-10.74%	0.34x	2.05x	$-195.90 Million
2024	-20.59%	-24.60%	0.42x	2.01x	$-291.33 Million

Industry Comparison

This section compares Evotec SE ADR's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $236,113,024
Average return on equity (ROE) among peers: -47.06%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Evotec SE ADR (EVO)	$800.14 Million	-35.26%	1.22x	$1.15 Billion
Aurora Cannabis Inc (ACB)	$602.92 Million	-11.50%	0.39x	$197.35 Million
Akanda Corp (AKAN)	$-3.83 Million	0.00%	0.00x	$1.51 Million
Akebia Ther (AKBA)	$74.01 Million	-330.87%	6.15x	$340.21 Million
Alkermes Plc (ALKS)	$54.20 Million	-73.99%	0.03x	$4.62 Billion
Amylyx Pharmaceuticals Inc (AMLX)	$-25.36 Million	0.00%	0.00x	$1.77 Billion
Amphastar P (AMPH)	$639.42 Million	21.51%	1.37x	$959.02 Million
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)	$346.79 Million	-104.36%	9.57x	$3.81 Billion
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)	$344.93 Million	26.40%	10.61x	$3.57 Billion
Anika Therapeutics Inc (ANIK)	$287.08 Million	1.44%	0.21x	$199.00 Million
ANI Pharmaceuticals Inc (ANIP)	$40.96 Million	0.73%	0.09x	$1.80 Billion

About Evotec SE ADR

NASDAQ:EVO USA Drug Manufacturers - Specialty & Generic

Market Cap

$1.15 Billion

Market Cap Rank

#8527 Global

#2320 in USA

Share Price

$3.23

Change (1 day)

-2.12%

52-Week Range

$2.31 - $4.73

All Time High

$26.53